Impact Therapeutics, Inc. (7630)

Overview

Impact Therapeutics, Inc. is a biopharmaceutical enterprise based in China, concentrating on the research, development, and commercialization of precision oncology therapies. With a focus on synthetic lethality, the company employs a targeted approach that exploits specific genetic vulnerabilities present in cancer cells, with the goal of providing highly selective anti-cancer treatments. Established in 2009 and headquartered in China, Impact Therapeutics operates within the biotechnology and medical research sectors, engaging with healthcare providers and patients through partnerships, clinical collaborations, and diverse commercialization efforts in the field of oncology.

Products and Services

• Senaparib
  

  Senaparib is Impact Therapeutics’ flagship commercial product, utilized as a first-line maintenance therapy for ovarian cancer within China. This therapy harnesses the principles of synthetic lethality to target the unique genetic characteristics of cancer cells, thus offering a more personalized treatment approach for patients.

• Pipeline of Small-Molecule Drug Candidates
  

  The company maintains an extensive pipeline of small-molecule drug candidates aimed at various oncological targets. These programs focus on critical areas such as:

  • PARP1/2
    

    Targeting PARP1/2 is crucial for inhibiting cancer cell survival following DNA damage, thereby enhancing the efficacy of existing therapies.

  • PARP1
    

    Standalone approaches utilizing PARP1 inhibition offer additional pathways to exploit cancer vulnerabilities.

  • ATR
    

    ATR inhibitors play a significant role in compromising the DNA damage response in cancer cells, facilitating increased susceptibility to treatments.

  • WEE1
    

    Targeting WEE1 leads to cell cycle dysregulation, promoting cancer cell death, especially in tumor types resistant to conventional chemotherapy.

  • PKMYT1/WEE1
    

    This combination approach enhances the effectiveness of chemotherapeutic agents by preventing the repair of DNA damage in rapidly dividing cancer cells.

  • DHX9
    

    DHX9 targeting is under exploration for its role in RNA metabolism, showcasing potential in overcoming resistance mechanisms in difficult-to-treat tumors.

  • ATM
    

    ATM inhibitors may enhance the death of cancer cells by promoting DNA damage, vital for therapy resistance in various malignancies.

  • USP1
    

    Targeting USP1 could influence the cellular mechanisms that protect tumor cells from DNA damage, representing a new frontier in treatment.

  • CHK1/2
    

    CHK1 and CHK2 inhibitors serve to obstruct cell cycle checkpoints, thereby amplifying the effects of DNA-damaging agents.